Biotech · Public company · Burlingame, CA, US

Enliven Therapeutics, Inc.

Ticker ELVN · SEC CIK 0001672619

Track this companyFree. Adds Enliven Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials33 recruiting or active

Pipeline programs10From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline10

5-FluorouracilPhase 1 · HER2-positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
CapecitabinePhase 1 · HER2-positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
ELVN-001Phase 1 · Chronic Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
ELVN-002Phase 1 · HER2 Mutant Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
ELVN-002Phase 1 · HER2-positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
EribulinPhase 1 · HER2-positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
Fam-Trastuzumab Deruxtecan-NxkiPhase 1 · HER2 Mutant Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
OxaliplatinPhase 1 · HER2-positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
TrastuzumabPhase 1 · HER2-positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
Trastuzumab emtansinePhase 1 · HER2 Mutant Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast CancerPHASE1 · ACTIVE_NOT_RECRUITING · started May 30, 2024ClinicalTrials.gov NCT06328738 · fetched Nov 12, 2026
ELVN-002 in HER2 Mutant Non-Small Cell Lung CancerPHASE1 · ACTIVE_NOT_RECRUITING · started Mar 20, 2023ClinicalTrials.gov NCT05650879 · fetched Nov 12, 2026
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid LeukemiaPHASE1 · RECRUITING · started May 22, 2022ClinicalTrials.gov NCT05304377 · fetched Nov 12, 2026